{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000014","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.404595+00:00","generated_at":"2026-06-03T00:35:46.267439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NovoCure Q1 net revenue up 13% to $138.5M; METIS trial meets endpoint, FDA decision on lung cancer PMA expected H2 2024","bullets":["Net revenue $138.5M (+13% YoY); net loss $38.8M ($0.36 loss per share); adjusted EBITDA -$4.6M.","Active patients 3,845; prescriptions received 1,643 (+10% YoY).","METIS Phase 3 met primary endpoint (brain metastases from NSCLC); will be presented at ASCO.","LUNAR PMA for Optune Lua in NSCLC: Day 100 FDA meeting productive, decision expected H2 2024.","Entered $400M senior secured credit facility with Pharmakon Advisors (non-dilutive)."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000014","json":"https://secwatch.observer/filing/0001645113-24-000014.json","markdown":"https://secwatch.observer/filing/0001645113-24-000014.md","text":"https://secwatch.observer/filing/0001645113-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/0001645113-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/nvcr-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:35:46.267439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9a6d96e04f7c87e74d2c69739b687379c1c8277","claim":"NovoCure Ltd reported quarter ended March 31, 2024 results: revenue $138.5 million, net income $38.8 million, EPS $0.36.","evidence_excerpt":"Total net revenues for the quarter were $138.5 million, an increase of 13% compared to the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/0001645113-24-000014-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$138.5 million"},{"label":"Net income","value":"$38.8 million"},{"label":"EPS","value":"$0.36"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}